The market for private, full-body health screenings has seen a surge in popularity, driven by consumers seeking early detection of potential medical issues. These scans, often marketed as 'MOTs' for the human body, promise to identify hidden health risks before symptoms appear. Proponents argue that this technology empowers patients to take control of their health and provides peace of mind through early intervention.

Conversely, many medical professionals and health organizations express skepticism. The primary concern is the high rate of 'incidentalomas'—findings that are technically abnormal but clinically insignificant. These false positives can lead to unnecessary anxiety, invasive follow-up procedures, and potential radiation exposure, which may ultimately cause more harm than the conditions they were intended to detect. Critics also point out that these scans are often expensive and not supported by robust clinical evidence as a routine screening tool for asymptomatic individuals.

While the BBC reports that some patients find these results life-changing, the medical community remains divided on whether the benefits of widespread private screening outweigh the risks of over-diagnosis and the strain on the healthcare system caused by managing non-urgent findings. The debate highlights a growing tension between consumer-driven healthcare and traditional, evidence-based medical practice.